Evidence map›Paper›PMID 40195420›Full record

ArticleScientific reports2025

CRISPR-Cas9 genetic screens reveal regulation of TMPRSS2 by the Elongin BC-VHL complex.

Ildar Gabaev, Alexandra Rowland, Emilija Jovanovic, Christian M Gawden-Bone, Thomas W M Crozier, Ana Teixeira-Silva, Edward J D Greenwood, Pehuén Pereyra Gerber, Niek Wit, James A Nathan and 2 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ildar GabaevDepartment of Medicine, University of Cambridge, Hills Road, Cambridge, CB2 0QQ, UK.
Alexandra RowlandDepartment of Medicine, University of Cambridge, Hills Road, Cambridge, CB2 0QQ, UK.
Emilija JovanovicWellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Puddicombe Way, Cambridge, CB2 0AW, UK.
Christian M Gawden-BoneDepartment of Medicine, University of Cambridge, Hills Road, Cambridge, CB2 0QQ, UK.
Thomas W M CrozierDepartment of Medicine, University of Cambridge, Hills Road, Cambridge, CB2 0QQ, UK.
Ana Teixeira-SilvaDepartment of Medicine, University of Cambridge, Hills Road, Cambridge, CB2 0QQ, UK.
Edward J D GreenwoodDepartment of Medicine, University of Cambridge, Hills Road, Cambridge, CB2 0QQ, UK.
Pehuén Pereyra GerberDepartment of Medicine, University of Cambridge, Hills Road, Cambridge, CB2 0QQ, UK.
Niek WitDepartment of Medicine, University of Cambridge, Hills Road, Cambridge, CB2 0QQ, UK.
James A NathanDepartment of Medicine, University of Cambridge, Hills Road, Cambridge, CB2 0QQ, UK.
Nicholas J MathesonDepartment of Medicine, University of Cambridge, Hills Road, Cambridge, CB2 0QQ, UK.
Paul J LehnerDepartment of Medicine, University of Cambridge, Hills Road, Cambridge, CB2 0QQ, UK. pjl30@cam.ac.uk.

Funding

Medical Research Council MR/V011561/1Wellcome Trust
6 · The paper itself

Abstract

The TMPRSS2 cell surface protease is used by a broad range of respiratory viruses to facilitate entry into target cells. Together with ACE2, TMPRSS2 represents a key factor for SARS-CoV-2 infection, as TMPRSS2 mediates cleavage of viral spike protein, enabling direct fusion of the viral envelope with the host cell membrane. Since the start of the COVID-19 pandemic, TMPRSS2 has gained attention as a therapeutic target for protease inhibitors which would inhibit SARS-CoV-2 infection, but little is known about TMPRSS2 regulation, particularly in cell types physiologically relevant for SARS-CoV-2 infection. Here, we performed an unbiased genome-wide CRISPR-Cas9 library screen, together with a library targeted at epigenetic modifiers and transcriptional regulators, to identify cellular factors that modulate cell surface expression of TMPRSS2 in human colon epithelial cells. We find that endogenous TMPRSS2 is regulated by the Elongin BC-VHL complex and HIF transcription factors. Depletion of Elongin B or treatment of cells with PHD inhibitors resulted in downregulation of TMPRSS2 and inhibition of SARS-CoV-2 infection. We show that TMPRSS2 is still utilised by SARS-CoV-2 Omicron variants for entry into colonic epithelial cells. Our study enhances our understanding of the regulation of endogenous surface TMPRSS2 in cells physiologically relevant to SARS-CoV-2 infection.

Indexed as

CRISPR-Cas SystemsSerine EndopeptidasesCOVID-19HumansSARS-CoV-2Serine EndopeptidasesTMPRSS2 protein, humanColon epithelial cellsCoronavirus entry factorsCRISPR-Cas9 screenHypoxic regulation of surface proteinsTransmembrane serine proteases

Identifiers

PMID40195420
PMCPMC11976923

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.